The Inhibitor of Death Receptor Signaling, Flice-Inhibitory Protein Defines a New Class of Tumor Progression Factors
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Death receptor–mediated apoptosis can be modulated by several antiapoptotic proteins, such as the FLICE (FADD [Fas-associated death domain]-like IL-1β–converting enzyme)-inhibitory proteins (FLIPs). The FLIP family includes both cellular and viral members. The Kaposi's sarcoma–associated herpesvirus protein (KSHV)-FLIP is expressed by human herpesvirus 8 (HHV-8), which is associated with malignancies such as Kaposi's sarcoma and certain lymphomas. In this paper, we demonstrate that KSHV-FLIP protects cells from Fas-mediated apoptosis by inhibiting caspase activation and permits clonal growth in the presence of death stimuli in vitro. Furthermore, we show that KSHV-FLIP can act as a tumor progression factor by promoting tumor establishment and growth in vivo. When injected into immunocompetent recipient mouse strains, murine B lymphoma cells (A20) transduced with KSHV-FLIP rapidly develop into aggressive tumors showing a high rate of survival and growth. The tumor-progressive activity of KSHV-FLIP is mediated by prevention of death receptor–induced apoptosis triggered by conventional T cells. Consequently, inhibitors of death receptor signaling can be regarded as a new class of tumor progression factors, and HHV-8–associated tumors may represent naturally occurring examples of the tumorigenic effect of such inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524 · cited 1×
“Excessive or impaired cell death strongly correlates to many disorders (4).”
BackgroundDeath Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 2×
“Upon death receptor ligation, intracellular adapter molecules, such as Fas-associated death domain (FADD)/MORT-1 (mediator of receptor-induced toxicity), 1 TRADD (TNFR1associated death domain protein), RIP (receptor interacting protein), and RAIDD (RIP-associated ICH-1/CED-3– homologous protein with a death domain) ar…”
BackgroundThe Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
Improved retroviral vectors for gene transfer and expression.
Miller, A. D., & Rosman, G. J. (1989) · PubMed · Cited by 1,971
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
Thome, M., Schneider, P., Hofmann, K., Fickenscher, H., Meinl, E., Neipel, F., Mattmann, C., Burns, K., Bodmer, J.-L., Schröter, M., et al. (1997) · Nature · doi:10.1038/386517a0 · Cited by 1,315
Cited by
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Apoptosis: a basic biological phenomenon with wide‐ranging implications in human disease
FADEEL, B., & ORRENIUS, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01570.x · Cited by 698
Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., & Kirchhoff, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101780200 · Cited by 566
FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis
Krueger, A., Baumann, S., Krammer, P. H., & Kirchhoff, S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.24.8247-8254.2001 · Cited by 549
Yeh, W.-C., Itie, A., Elia, A. J., Ng, M., Shu, H.-B., Wakeham, A., Mirtsos, C., Suzuki, N., Bonnard, M., Goeddel, D. V., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80214-9 · Cited by 515
“Elevated expression of Casper has recently been linked to the escape of tumors from immune surveillance (Djerbi et al., 1999; Medema et al., 1999) and the resistance of early activated T cells and differentiating macrophages to cell death (Irmler et al., 1997; Refaeli et al., 1998; Perlman et al.,…”
BackgroundLeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 507
The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex
Micheau, O., Thome, M., Schneider, P., Holler, N., Tschopp, J., Nicholson, D. W., Briand, C., & Grütter, M. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206882200 · Cited by 482
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Aoki, Y., Feldman, G. M., & Tosato, G. (2003) · Blood · doi:10.1182/blood-2002-07-2130 · Cited by 438
Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications
Jost, P. J., & Ruland, J. (2007) · Blood · doi:10.1182/blood-2006-07-025809 · Cited by 408
KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine
Ganem, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40567 · Cited by 385
Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Gene Expression as Revealed by DNA Arrays
Jenner, R. G., Albà, M. M., Boshoff, C., & Kellam, P. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.891-902.2001 · Cited by 379
Regulation of lymphocyte proliferation and death by flip
Thome, M., & Tschopp, J. (2001) · Nature Reviews Immunology · doi:10.1038/35095508 · Cited by 378
Montaner, S., Sodhi, A., Molinolo, A., Bugge, T. H., Sawai, E. T., He, Y., Li, Y., Ray, P. E., & Gutkind, J. S. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00237-4 · Cited by 373
Medema, J. P., de Jong, J., Peltenburg, L. T. C., Verdegaal, E. M. E., Gorter, A., Bres, S. A., Franken, K. L. M. C., Hahne, M., Albar, J. P., Melief, C. J. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201398198 · Cited by 356
Dourmishev, L. A., Dourmishev, A. L., Palmeri, D., Schwartz, R. A., & Lukac, D. M. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.2.175-212.2003 · Cited by 352
RETRACTED: KSHV vFLIP Is Essential for the Survival of Infected Lymphoma Cells
Guasparri, I., Keller, S. A., & Cesarman, E. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031467 · Cited by 324
Retractedvan Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 309
Viral Latency and Its Regulation: Lessons from the γ-Herpesviruses
Speck, S. H., & Ganem, D. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.06.014 · Cited by 302
KSHV INFECTION AND THE PATHOGENESIS OF KAPOSI'S SARCOMA
Ganem, D. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100133 · Cited by 298
A time to kill: viral manipulation of the cell death program
Hay, S., & Kannourakis, G. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-7-1547 · Cited by 290
Regulation of death receptor-mediated apoptosis pathways
Schmitz, I., Kirchhoff, S., & Krammer, P. H. (2000) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(00)00048-0 · Cited by 288
cFLIP regulation of lymphocyte activation and development
Budd, R. C., Yeh, W.-C., & Tschopp, J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1787 · Cited by 280
Kovalovich, K., Li, W., DeAngelis, R., Greenbaum, L. E., Ciliberto, G., & Taub, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100740200 · Cited by 280
You, Z., Ouyang, H., Lopatin, D., Polver, P. J., & Wang, C.-Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102464200 · Cited by 127
Metadata
- Authors
- Djerbi, M., Screpanti, V., Catrina, A. I., Bogen, B., Biberfeld, P., & Grandien, A.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1999-10-04
- Volume
- 190
- Issue
- 7
- Pages
- 1025-1032
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2018091905
- Cited by
- 421
- References
- 24
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.